Pair Name | Parthenolide, Doxorubicin | ||
Phytochemical Name | Parthenolide (PubChem CID: 7251185 ) | ||
Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Parthenolide, Doxorubicin | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Inhibition-->Overexpression of both Nrf2 and its target activities | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Down-regulation | Expression | HSPA4 | hsa3308 | |
Down-regulation | Expression | NFE2L2 | hsa4780 | |
Down-regulation | Expression | SOD2 | hsa6648 | |
In Vitro Model | MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 |
Result | PN prevented the acquisition of resistance induced by Mitox and DOX treatment in MDA-MB231 cells. This effect was mediated by inhibition of overexpression of both Nrf2 and its target activities. Therefore, within MDA-MB231 cell lines, PN not only exerts toxic effects on stem-like cells, which are responsible for tumour recurrence, but also prevents drug resistance |
No. | Title | Href |
---|---|---|
1 | Parthenolide prevents resistance of MDA-MB231 cells to doxorubicin and mitoxantrone: the role of Nrf2. Cell Death Discov. 2017;3:17078. Published 2017 Dec 4. doi:10.1038/cddiscovery.2017.78 | Click |